Abstract 87P
Background
Survival outcome in rectal cancer primarily determined by nodal status and stage of tumour. Though nodal invasion is strong prognostic indicator in rectal cancer, there exists marked heterogenecity within stage III patients. We investigated the prognostic impact of ratio of positive lymph nodes to total number of retrieved nodes (LNR), ratio of positive to negative lymph nodes (PN-LNR) and negative to positive nodes (NP-LNR) on survival in patients with node positive rectal cancers.
Methods
This is a retrospective analysis of 336 patients of rectal cancer who underwent surgery and adjuvant therapy between 2011 to 2014. The node positive patients were grouped into two groups based on quartiles of LNR <0.2 and >0.2, PN-LNR <0.36 and >0.36 and NP-LNR <2.38 and >2.38. The association between LNR, PN-LNR and NP-LNR and survival was evaluated by the Kaplan-Meier method and multivariate analysis with covariates of prognostic significance in univariate analysis.
Results
Patients classified as LNR <0.2 and >0.2 had a 5-year OS of 86.8 and 64.4 (p < 0.001) and DFS of 85.4 and 59.9 respectively (p < 0.001). The 5-year OS rate for PN-LNR <0.36 and >0.36 were 85.1 and 55.1 (p < 0.001) and DFS of 83.9 and 49.3 respectively (p < 0.001). The 5-year OS rate for NP-LNR <2.38 and >2.38 were 53.1 and 87.3 (p < 0.001) and DFS of 47.5 and 85.6 respectively (p < 0.001). OS and DFS of stage III A, III B, III C were 80.3,75.3, and 53.3 (p < 0.001) and 79.5,71.8 and 47.8 respectively (p < 0.001). On univariate analysis, pN status, sex, grade, histology of tumour, LNR, PN-LNR, NP-LNR were found to be significator factors for OS. On multivariate analysis, NP-LNR was found to be significant factor for OS. (p < 0.001, HR = 17.857; [3.557-89.657]). Factors that were found to be significant for DFS were pN status, LNR, PN-LNR, NP-LNR on univariate analysis and NP-LNR on multivariate analysis. (p < 0.001, HR = 11.41; [1.928-67.634]). NP-LNR is found to a significant factor for OS and DFS both on univariate and multivariate analysis.
Conclusions
The NP-LNR was recognised as an independent prognostic factor in node positive rectal cancer patients. Hence, it can be used as an independent prognostic factor and permits superior prognostic stratification in stage III rectal cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Kidwai Memorial Institute of Oncology.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
508P - Efficacy and safety of anti-PD-1 antibody SHR-1210 combined with apatinib in first-line treatment for advanced lung squamous carcinoma: A phase II study
Presenter: Jinliang Wang
Session: Poster display session
Resources:
Abstract
525P - Retrospective analysis of outcomes of cisplatin and irinotecan combination chemotherapy for unresectable thymic carcinoma
Presenter: Akito Fukuda
Session: Poster display session
Resources:
Abstract
524P - A study in recurrent small cell lung cancer patients, comparing weekly paclitaxel, irinotecan and temozolomide in second-line: A prospective study from a south Indian tertiary cancer hospital
Presenter: LALATENDU MOHARANA
Session: Poster display session
Resources:
Abstract
505P - PD-L1 expression in ALK rearranged NSCLC: All questions answered?
Presenter: Amrith B P
Session: Poster display session
Resources:
Abstract
487P - Afatinib versus gefitinib or erlotinib in first-line setting for Malaysia patients with EGFR mutant advanced lung adenocarcinoma
Presenter: Chee Shee Chai
Session: Poster display session
Resources:
Abstract
492P - Feasibility of rebiopsy and sequential treatment of EGFR tyrosine kinase inhibitors in real world patients with EGFR mutant non-small cell lung cancer
Presenter: Heekyung Ahn
Session: Poster display session
Resources:
Abstract
513P - Phase II study of vitamin B12 and folate supplementation for patients undergoing chemotherapy with pemetrexed
Presenter: Shingo Kitagawa
Session: Poster display session
Resources:
Abstract
493P - Is exon 19 deletion different from exon 21 mutation in advanced non-small cell lung cancer: A single centre experience
Presenter: Sarita Shrivastva
Session: Poster display session
Resources:
Abstract
494P - Comparison of pattern of disease progression and prevalence of acquired T790M mutation in Malaysia patients with EGFR mutant lung adenocarcinoma upon failure of first-line afatinib, gefitinib and erlotinib
Presenter: Chee Shee Chai
Session: Poster display session
Resources:
Abstract
517P - High BRCA1 expression is independently correlated with decreased overall survival in lung adenocarcinoma: Evidence from meta and bioinformatics analyses
Presenter: Fengzhu Guo
Session: Poster display session
Resources:
Abstract